BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36605432)

  • 1. Symptomatic bone marrow metastases in breast cancer: A retrospective cohort study.
    Yang R; Jia L; Lu G; Lv Z; Cui J
    Front Oncol; 2022; 12():1042773. PubMed ID: 36605432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10-year, single-center, real-world study of 67 cases.
    Niu L; Lv H; Zhang M; Zeng H; Fu S; Cui S; Liu Z; Yan M
    Cancer Med; 2023 May; 12(9):10672-10683. PubMed ID: 36951543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study.
    Yang R; Lu G; Lv Z; Jia L; Cui J
    Front Oncol; 2022; 12():1048781. PubMed ID: 36330468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic evaluation of breast cancer patients with evident bone marrow metastasis.
    Demir L; Akyol M; Bener S; Payzin KB; Erten C; Somali I; Can A; Dirican A; Bayoglu V; Kucukzeybek Y; Alacacioglu A; Calli AO; Tarhan MO
    Breast J; 2014; 20(3):279-87. PubMed ID: 24673811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
    Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
    ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis.
    Zhang L; Zhang J; Li Z; Wu Y; Tong Z
    Oncol Lett; 2020 Oct; 20(4):92. PubMed ID: 32831911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients.
    Langer I; Guller U; Worni M; Berclaz G; Singer G; Schaer G; Fehr MK; Hess T; Viehl C; Bronz L; Schnarwyler B; Wight E; Infanger E; Burger D; Koechli OR; Zuber M;
    Ann Surg Oncol; 2014 Feb; 21(2):401-7. PubMed ID: 24145993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
    Badaoui S; Kichenadasse G; Rowland A; Sorich MJ; Hopkins AM
    Oncologist; 2021 Jul; 26(7):562-568. PubMed ID: 33914991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
    Lin S; Mo H; Li Y; Guan X; Chen Y; Wang Z; Xu B
    BMC Cancer; 2021 Dec; 21(1):1330. PubMed ID: 34906122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.